Tumor-Targeted Therapy with BRAF-Inhibitor Recruits Activated Dendritic Cells to Promote Tumor Immunity in Melanoma

Scientists investigated therapy-mediated immunological alterations in the tumor microenvironment and tumor-draining lymph nodes in the D4M.3A preclinical melanoma mouse model by using high-dimensional multicolor flow cytometry in combination with multiplex immunohistochemistry.